Logo image of ADPT

ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Fundamental Analysis

NASDAQ:ADPT - Nasdaq - US00650F1093 - Common Stock - Currency: USD

9.06  -0.03 (-0.33%)

Fundamental Rating

2

Taking everything into account, ADPT scores 2 out of 10 in our fundamental rating. ADPT was compared to 56 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of ADPT have multiple concerns. While showing a medium growth rate, ADPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADPT had negative earnings in the past year.
ADPT had a negative operating cash flow in the past year.
In the past 5 years ADPT always reported negative net income.
ADPT had a negative operating cash flow in each of the past 5 years.
ADPT Yearly Net Income VS EBIT VS OCF VS FCFADPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

ADPT's Return On Assets of -27.76% is on the low side compared to the rest of the industry. ADPT is outperformed by 73.21% of its industry peers.
The Return On Equity of ADPT (-74.49%) is worse than 76.79% of its industry peers.
Industry RankSector Rank
ROA -27.76%
ROE -74.49%
ROIC N/A
ROA(3y)-29%
ROA(5y)-24.51%
ROE(3y)-64.95%
ROE(5y)-49.77%
ROIC(3y)N/A
ROIC(5y)N/A
ADPT Yearly ROA, ROE, ROICADPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Gross Margin of ADPT (62.53%) is better than 87.50% of its industry peers.
In the last couple of years the Gross Margin of ADPT has declined.
The Profit Margin and Operating Margin are not available for ADPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
ADPT Yearly Profit, Operating, Gross MarginsADPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADPT has been increased compared to 1 year ago.
ADPT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ADPT has a worse debt to assets ratio.
ADPT Yearly Shares OutstandingADPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
ADPT Yearly Total Debt VS Total AssetsADPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ADPT has an Altman-Z score of -1.18. This is a bad value and indicates that ADPT is not financially healthy and even has some risk of bankruptcy.
ADPT's Altman-Z score of -1.18 is on the low side compared to the rest of the industry. ADPT is outperformed by 83.93% of its industry peers.
A Debt/Equity ratio of 0.69 indicates that ADPT is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.69, ADPT is doing worse than 71.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF N/A
Altman-Z -1.18
ROIC/WACCN/A
WACC10.65%
ADPT Yearly LT Debt VS Equity VS FCFADPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

ADPT has a Current Ratio of 2.92. This indicates that ADPT is financially healthy and has no problem in meeting its short term obligations.
ADPT has a Current ratio (2.92) which is comparable to the rest of the industry.
A Quick Ratio of 2.82 indicates that ADPT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.82, ADPT is in line with its industry, outperforming 53.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.82
ADPT Yearly Current Assets VS Current LiabilitesADPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.72% over the past year.
The Revenue has grown by 8.61% in the past year. This is quite good.
ADPT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.03% yearly.
EPS 1Y (TTM)26.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.39%
Revenue 1Y (TTM)8.61%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%25.24%

3.2 Future

The Earnings Per Share is expected to grow by 18.03% on average over the next years. This is quite good.
ADPT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.31% yearly.
EPS Next Y21.75%
EPS Next 2Y17.82%
EPS Next 3Y18.03%
EPS Next 5YN/A
Revenue Next Year23.44%
Revenue Next 2Y21.9%
Revenue Next 3Y22.84%
Revenue Next 5Y19.31%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADPT Yearly Revenue VS EstimatesADPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
ADPT Yearly EPS VS EstimatesADPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADPT Price Earnings VS Forward Price EarningsADPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADPT Per share dataADPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ADPT's earnings are expected to grow with 18.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.82%
EPS Next 3Y18.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAPTIVE BIOTECHNOLOGIES

NASDAQ:ADPT (5/22/2025, 10:05:40 AM)

9.06

-0.03 (-0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners94.45%
Inst Owner Change6.18%
Ins Owners2.19%
Ins Owner Change-0.01%
Market Cap1.38B
Analysts82.86
Price Target11.56 (27.59%)
Short Float %6.21%
Short Ratio3.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.48%
Min EPS beat(2)12%
Max EPS beat(2)32.96%
EPS beat(4)4
Avg EPS beat(4)19.72%
Min EPS beat(4)8.94%
Max EPS beat(4)32.96%
EPS beat(8)7
Avg EPS beat(8)12.59%
EPS beat(12)10
Avg EPS beat(12)12.47%
EPS beat(16)14
Avg EPS beat(16)11.8%
Revenue beat(2)2
Avg Revenue beat(2)10.77%
Min Revenue beat(2)1.07%
Max Revenue beat(2)20.47%
Revenue beat(4)4
Avg Revenue beat(4)11.07%
Min Revenue beat(4)1.07%
Max Revenue beat(4)20.47%
Revenue beat(8)6
Avg Revenue beat(8)4.52%
Revenue beat(12)8
Avg Revenue beat(12)2.87%
Revenue beat(16)12
Avg Revenue beat(16)3.91%
PT rev (1m)15.25%
PT rev (3m)49.45%
EPS NQ rev (1m)3.55%
EPS NQ rev (3m)2.06%
EPS NY rev (1m)9.35%
EPS NY rev (3m)9.23%
Revenue NQ rev (1m)4.49%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)3.14%
Revenue NY rev (3m)4.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.26
P/FCF N/A
P/OCF N/A
P/B 7.23
P/tB 20.11
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS1.25
BVpS1.25
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.76%
ROE -74.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.53%
FCFM N/A
ROA(3y)-29%
ROA(5y)-24.51%
ROE(3y)-64.95%
ROE(5y)-49.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.18%
Cap/Sales 1.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.82
Altman-Z -1.18
F-Score4
WACC10.65%
ROIC/WACCN/A
Cap/Depr(3y)48.38%
Cap/Depr(5y)161.41%
Cap/Sales(3y)5.71%
Cap/Sales(5y)15.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.39%
EPS Next Y21.75%
EPS Next 2Y17.82%
EPS Next 3Y18.03%
EPS Next 5YN/A
Revenue 1Y (TTM)8.61%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%25.24%
Revenue Next Year23.44%
Revenue Next 2Y21.9%
Revenue Next 3Y22.84%
Revenue Next 5Y19.31%
EBIT growth 1Y29.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.37%
EBIT Next 3Y26.5%
EBIT Next 5YN/A
FCF growth 1Y54.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.22%
OCF growth 3YN/A
OCF growth 5YN/A